Bioconjugates

ADCs can be described as a new rising star among biopharmaceutics. They are able to specifically target and destroy cancer cells very effectively. Their levels of toxicity can vary depending on several factors, including their specific design and the potency of the cytotoxic drug. This is why safe handling in between facilities is such an important issue and must not be taken lightly.

ADCs offer new, highly promising approaches in the therapy of various cancer types, and the number of approved ADCs is continuously growing. In this article, we will have a look at ADCs currently approved.

Bioconjugates are powerful tools in several areas of life sciences and beyond. In this article, we will have a look at the technology in general as well as at examples of bioconjugates in specific fields.

Depending on their constituents, ADCs are extremely variable and can be used for several, very distinct purposes. In this article, we will present you 5 examples of ADCs and their respective characteristics.

ADC technology has revolutionized several fields in medicine and research. In this article, we will shed light on this groundbreaking technology.

Antibody drug conjugates (ADCs) are a rapidly growing field of interest in biopharmaceutics. In comparison to conventional chemotherapy treatments, ADCs have the potential to destroy cancerous cells without damaging healthy cells in the process. In this article we will give you an introduction to this important and rapidly growing field. 

The safe handling of ADCs or other HPAPIs is a complex and elaborate process that requires specialized facilities and a safe, sterile environment. The filling/aliquoting step in particular calls for great care and specific equipment to ensure sterility and rule out any potential cross-contamination as well as potential harm to handling staff.

The manufacturing of bioconjugates is a complex process that involves linking a drug payload with a targeting moiety using a linker. The process is highly specific and requires careful optimization to ensure that the bioconjugate is effective and safe for use in patients. Single-use technology has revolutionized the manufacturing of bioconjugates by offering a range of benefits over traditional stainless-steel manufacturing. Therefore, this article will pay special attention to this subject. 

Scale-up and industrial production of ADCs face complications due to the high safety measures which need to be taken to guarantee product efficacy and a protected working environment for staff and manufacturers. In this article we seek out to give you an overview of the different challenges during ADC manufacturing while also introducing solutions which help to ensure aseptic production methods through single-use-technologies and end-to-end systems. 

Bioconjugation is a pharmaceutical technique that is gaining more and more importance, most of all in cancer therapy. In this article, we will provide some basic information on bioconjugation, but also discuss major challenges related to this field.
 

Since the first ADCs entered clinical trials in the 1990s, they have shown great promise in treating a variety of cancers and other diseases. However, the development of ADCs has also been marked by challenges and setbacks, including issues with efficacy, safety, and manufacturing. In this article, we will explore the history of ADCs, from their early development to the latest advances in technology and applications.

Antibody-Drug Conjugates are rather novel and exciting biopharmaceutical agents. This article will give you an overview of what is to know about ADCs – find out more!